Corporate Presentation
July 2014

Geron Analyst and Investor Meeting at ASH 2013


2013 Annual Report
Download here

Corporate Profile
Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Recent NewsMore >>
08/11/14Geron Corporation Reports Second Quarter 2014 Financial ResultsPrinter Friendly Version
08/05/14Geron to Assume Sponsorship of Myelofibrosis IST and INDPrinter Friendly Version
07/30/14Geron Announces Conference Call to Discuss Second Quarter 2014 Financial ResultsPrinter Friendly Version
Upcoming EventsMore >>
To be announced.
Stock Information
GERN (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Up 0.07 (3.32%)
Data as of 10/20/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Contact Information

Anna Krassowska, Ph.D.
Tel: 650-473-7765
E-mail: or

RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | Financial Tear Sheet Financial Tear Sheet
Form content here please :)